CN112824397A - Lomefloxacin allyl ketone derivative and preparation method and application thereof - Google Patents
Lomefloxacin allyl ketone derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN112824397A CN112824397A CN201911139921.5A CN201911139921A CN112824397A CN 112824397 A CN112824397 A CN 112824397A CN 201911139921 A CN201911139921 A CN 201911139921A CN 112824397 A CN112824397 A CN 112824397A
- Authority
- CN
- China
- Prior art keywords
- lomefloxacin
- formula
- allyl ketone
- preparation
- ketone derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a lomefloxacin allyl ketone derivative, a preparation method and an application thereof, wherein the formula I is shown as the following chemical structure general formula:
Description
Technical Field
The invention belongs to the technical field of innovative medicine synthesis, and particularly relates to a lomefloxacin allyl ketone derivative, a preparation method of the lomefloxacin allyl ketone derivative, and application of the lomefloxacin allyl ketone derivative in antitumor medicines.
Background
New drug innovation stems from the discovery of leads, and rational drug molecular design based on structure or mechanism is an effective method for discovering leads. In the drug effect groups with various structures, the acrylketone structure is not only the characteristic structure of a chalcone compound which is a natural effective component, but also the characteristic drug effect group of a targeted antitumor drug sunitinib. Therefore, compounds constructed with acrylketone as a structural fragment and having various pharmacological activities have been attracting attention. However, most of natural chalcone compounds are multi-hydroxyl benzene ring substituted propenone compounds, and the poor water solubility of the compounds causes low bioavailability and limits clinical application. In addition, the topoisomerase which is an action target point of the antibacterial fluoroquinolone medicine is also an important action target point of the antitumor medicine, the antibacterial activity of the antibacterial fluoroquinolone medicine can be converted into the antitumor activity, and the fluoroquinolone C-3 carboxyl is not a pharmacophore required by the antitumor activity and can be replaced by a biological electron isostere to improve the antitumor activity of the fluoroquinolone medicine. However, the research on the replacement of the C-3 carboxyl group of fluoroquinolone with aryl acrylketone has not been reported. Based on the above, in order to improve the water solubility of chalcone, hydrophilic piperazinyl is introduced to increase the water solubility and improve the bioavailability and the bioactivity of the chalcone, the invention uses the skeleton of the dominant pharmacophore of the lomefloxacin fluoroquinolone medicine, namely 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one, as a substituent of an aryl propenone structure, and further designs the derivatives of the fluoroquinolone chalcone with a novel structure, namely chalcone.
Therefore, the invention aims to provide the lomefloxacin allyl ketone derivative with the anti-tumor effect and efficacy and also provides a preparation method of the lomefloxacin allyl ketone derivative.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: the allyl ketone derivative of lomefloxacin has a chemical structural formula shown as a general formula I:
in the formula I, Ar is a benzene ring or a substituted benzene ring or a furan ring or a pyridine ring, and the compound is a compound with the following specific structure:
the preparation method of the allyl ketone derivative of lomefloxacin provided by the invention is prepared by taking commercially obtained lomefloxacin shown in a formula II as a raw material;
the preparation method comprises the following specific steps:
1) the commercially available lomefloxacin shown in a formula II is used as a raw material to prepare a lomefloxacin imidazole amide compound shown in a formula III through a reaction with Carbonyldiimidazole (CDI), and the preparation method comprises the following steps:
21.0g (60.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-carboxylic acid II is dissolved in 500mL of anhydrous acetonitrile, 15.2g (94.0mmol) of carbonyldiimidazole is added, and the mixed reaction is stirred in a water bath and refluxed until the raw material II disappears. Standing at room temperature, filtering to collect the generated solid, and recrystallizing with acetone to obtain the aceclomethacin imidazole amide light yellow crystal shown as the formula III, wherein the yield is 74.8%, and the m.p.231-233 ℃.1H NMR(400MHz,CD3Cl)δ：1.41～1.52(6H,m,2×CH3) 2.85-3.57 (7H, m, piperazine-H), 4.68(2H, q, N-CH)2) 7.46-7.70 (2H, m, imidazole-H), 7.85(1H, d, 5-H), 8.26(1H, s, imidazole-H), 8.87(1H, s, 2-H); MS (m/z): 402[ M + H [ ]]+Calculating (C)20H21F2N5O2)：401.42。
As a further improvement, the molar ratio of the lomefloxacin represented by the formula II to the carbonyldiimidazole is 1: 1.0-2.0, and the solvent can be at least one of acetonitrile, tetrahydrofuran, dioxane and dimethylformamide or a mixed solvent of the two.
2) The preparation method comprises the following steps of carrying out condensation reaction on lomefloxacin imidazole amide shown in a formula III and monoethyl malonate potassium salt under the catalysis of triethylamine-magnesium chloride to obtain a lomefloxacin C-3 formyl ethyl acetate compound shown in a formula IV, wherein the preparation method comprises the following specific steps:
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (1H-imidazole-1-formyl) - [ quinolin-4 (1H) -one, 15.6g (39.0mmol) of formula III, 6.6g (69.1mmol) of magnesium chloride and 8.3g (49.0mmol) of potassium monoethyl malonate are sequentially added into 600mL of anhydrous acetonitrile, 12.2g (12.0mmol) of triethylamine is added dropwise with stirring in an ice bath, and the mixed reaction is stirred in a water bath and refluxed until the raw material III disappears. The solvent was evaporated under reduced pressure, 500mL of water was added, the mixture was extracted with methylene chloride (3X 150mL), the organic phases were combined, washed with water (3X 200mL), washed with saturated brine (2X 150mL), and dried over anhydrous sodium sulfate. And recovering dichloromethane at normal pressure, and recrystallizing the residue with absolute ethyl alcohol to obtain a white crystal shown as a formula IV, wherein the yield is 73.4%, and m.p.226-228 ℃.1H NMR(400MHz,CD3Cl)δ：1.32～1.57(9H，m，3×CH3) 2.84-3.55 (7H, m, piperazine-H), 4.16(2H, s, COCH)2CO)，4.28(2H，q，CO2CH2)，4.67(2H，q，N-CH2)，7.84(1H，d，5-H)，8.87(1H，s,2-H)；MS(m/z)：422[M+H]+Calculating (C)21H25F2N3O4)：421.45。
3) The C-3 ethyl formylacetate compound of the lomefloxacin shown in the formula IV is subjected to hydrolysis decarboxylation reaction by using a sodium hydroxide aqueous solution with the mass fraction of 6 percent, so that the C-3 ethanone compound of the lomefloxacin shown in the formula V can be conveniently prepared, and the specific preparation method is as follows:
taking 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-formylacetic acid ethyl ester formula IV 10g (23.0mmol) was suspended in 200mL of a 6% by mass aqueous solution of sodium hydroxide, and the reaction was stirred in an oil bath under reflux until the disappearance of the raw material IV. Standing at room temperature, filtering to collect the generated solid, washing with water to be neutral, drying, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal of formula V, wherein the yield is 78.2%, and m.p.235-237 ℃.1H NMR(400MHz,CD3Cl)δ：1.36～1.55(6H,m,2×CH3)，2.45(3H，s，COCH3) 2.88 to 3.56(7H, m, piperazine-H), 4.68(2H, q, N-CH)2)，7.86(1H，d，5-H)，8.86(1H，s,2-H)；MS(m/z)：350[M+H]+Calculating (C)18H21F2N3O2)：349.38。
4) C-3 ethanone of lomefloxacin shown in a formula V and aromatic aldehyde are subjected to Claisen-Schmidt aldol condensation reaction in absolute ethyl alcohol under the catalysis of alkali, and after the reaction is completed, a target compound is obtained by treatment, wherein the target compound is shown in a formula I, and the specific process is as follows:
wherein Ar in the formula I is a benzene ring or a substituted benzene ring or a furan ring or a pyridine ring.
The general synthetic preparation procedure for the target compound of formula i is: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and an aromatic aldehyde (3.0mmol) and a base catalyst piperidine (0.1mL) were added. And (3) refluxing and reacting the mixed reactants for 15-24 h, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal shown in the formula I.
As a further improvement, the mol ratio of the lomefloxacin C-3 ethanone shown in the formula V to the aromatic aldehyde is 1: 1.0-1.5.
The base catalyst is at least one of piperidine, pyridine, triethylamine, morpholine, potassium acetate, sodium hydroxide ethanol solution or potassium hydroxide ethanol solution.
The lomefloxacin allyl ketone derivative is applied to preparing antitumor drugs.
The anti-tumor drug is a drug for treating human non-small cell lung cancer, kidney cancer, liver cancer, stomach cancer, pancreatic cancer or leukemia.
The lomefloxacin allyl ketone derivative is designed and synthesized by effectively combining a fluoroquinolone skeleton and an aryl allyl ketone pharmacophore based on the split principle of the pharmacophores, realizes the complementation and activity superposition of the pharmacophores with different structures, achieves the effects of synergism, toxicity reduction and drug resistance, and can be developed as an anti-tumor drug with a brand new structure.
Detailed Description
Example 1
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3-cinnamoyl-quinolin-4 (1H) -one (I-1) having the chemical formula:
namely, Ar in the formula I is phenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.40g (3.8mmol) of benzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) refluxing and reacting the mixed reactants for 18h, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-1, wherein the yield is 68.4%, and the m.p.234-236 ℃.1H NMR(400MHz,CD3Cl)δ：1.42～1.57(6H,m,2×CH3) 2.87 to 3.55(7H, m, piperazine-H), 4.68(2H, q, N-CH)2) 7.46-8.05 (7H, m, Ph-H, 5-H and 2 '-H), 8.55(1H, d, 3' -H),8.88(1H, s, 2-H); MS (m/z): 438[ M + H]+Calculating (C)25H25F2N3O2)：437.49。
Example 2
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (4-methoxycinnamoyl) -quinolin-4 (1H) -one (I-2) having the chemical formula:
namely, Ar in the formula I is p-methoxyphenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.57g (4.2mmol) of 4-methoxybenzaldehyde and piperidine, a basic catalyst (0.1mL) were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-2, wherein the yield is 75.6%, and the m.p.238-240 ℃.1H NMR(400MHz,CD3Cl)δ：1.42～1.62(6H,m,2×CH3) 3.12 to 3.62(7H, m, piperazine-H), 3.89(3H, s, OCH)3),4.71(2H，q，N-CH2) 7.46-8.16 (6H, m, Ph-H, 5-H and 2 '-H), 8.62(1H, d, 3' -H),8.95(1H, s, 2-H); MS (m/z): 468[ M + H]+Calculating (C)26H27F2N3O3)：467.52。
Example 3
1-ethyl-6, 8-difluoro-7- (4-acetylpiperazin-1-yl) -3- (3, 4-dioxocinnamoyl) -quinolin-4 (1H) -one (I-3) having the chemical formula:
namely, Ar in the formula I is 3,4- (dioxymethylene) phenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.53g (3.5mmol) of 3, 4-dioxytolualdehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-3, wherein the yield is 81.6%, and the m.p.244-246 ℃.1H NMR(400MHz,CD3Cl)δ：1.45～1.66(6H,m,2×CH3) 3.17 to 3.65(7H, m, piperazine-H), 4.70(2H, q, N-CH)2)，6.22(2H，s，OCH2O), 7.46-8.12 (5H, m, Ph-H, 5-H and 2 '-H), 8.62(1H, d, 3' -H),8.97(1H, s, 2-H); MS (m/z): 482[ M + H ]]+Calculating (C)26H25FN3O4)：481.50。
Example 4
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (3,4, 5-trimethoxycinnamoyl) -quinolin-4 (1H) -one (I-4) having the chemical formula:
namely, Ar in the formula I is 3,4, 5-trimethoxyphenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.63g (3.2mmol) of 3,4, 5-trioxybenzaldehyde and piperidine (0.1mL) as an alkali catalyst were added. And (3) refluxing and reacting the mixed reactants for 20 hours, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-4, wherein the yield is 64.7%, and the m.p.232-234 ℃.1H NMR(400MHz,CD3Cl)δ：1.38～1.62(6H,m,2×CH3) 2.86 to 3.57(7H, m, piperazine-H), 3.88, 3.93(9H, 2s, 3 XOCH)3)，4.70(2H，q，N-CH2) 7.48 to 8.07(4H, m, Ph-H, 5-H and 2 '-H), 8.57(1H, d, 3' -H),8.92(1H, s, 2-H); MS (m/z): 528[ M + H ]]+Calculating (C)28H31FN3O5)：527.57。
Example 5
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (4-methylcinnamoyl) -quinolin-4 (1H) -one (I-5) having the chemical formula:
namely, Ar in the formula I is p-methyl-phenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.58g (4.8mmol) of 4-methylbenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 15h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-5, wherein the yield is 65.0%, and the m.p.223-225 ℃.1H NMR(400MHz,CD3Cl)δ：1.38～1.56(6H,m,2×CH3)，2.33(3H，s，Ph-CH3) 2.78 to 3.55(7H, m, piperazine-H), 4.68(2H, q, N-CH)2) 7.42-7.87 (6H, m, Ph-H, 5-H and 2 '-H), 8.57(1H, d, 3' -H),8.86(1H, s, 2-H); MS (m/z): 452[ M + H]+Calculating (C)26H27FN3O2)：451.52。
Example 6
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (4-fluorocinnamoyl) -quinolin-4 (1H) -one (I-6) having the chemical formula:
namely, Ar in the formula I is p-fluoro-phenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.48g (3.8mmol) of 4-fluorobenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 15h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-6, wherein the yield is 83.6%, and the m.p.242-244 ℃.1H NMR(400MHz,CD3Cl)δ：1.45～1.67(6H,m,2×CH3) 3.12 to 3.67(7H, m, piperazine-H), 4.74(2H, q, N-CH)2) 7.50-8.14 (6H, m, Ph-H, 5-H and 2 '-H), 8.65(1H, d, 3' -H),8.97(1H, s, 2-H); MS (m/z): 456[ M + H ]]+Calculating (C)25H24F3N3O2)：455.48。
Example 7
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (4-chlorocinnamoyl) -quinolin-4 (1H) -one (I-7) having the chemical formula:
namely, Ar in the formula I is p-chlorophenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -1-yl-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.45g (3.2mmol) of 4-chlorobenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-7, wherein the yield is 75.6%, and the m.p. is 233-235 ℃.1H NMR(400MHz,CD3Cl)δ：1.43～1.65(6H,m,2×CH3) 3.15 to 3.63(7H, m, piperazine-H), 4.71(2H, q, N-CH)2) 7.48 to 8.10(6H, m, Ph-H, 5-H and 2 '-H), 8.62(1H, d, 3' -H),8.96(1H, s, 2-H); MS (m/z): 472[ M + H]+(35Cl), calculating (C)25H24F2ClN3O2)：471.94。
Example 8
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (4-bromocinnamoyl) -quinolin-4 (1H) -one (I-8) having the chemical formula:
namely, Ar in the formula I is p-bromophenyl.
The preparation method of the compound comprises the following steps: dissolving 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V in 20mL of absolute ethyl alcohol, adding 0.67g (3.6mmol) of 4-bromobenzaldehyde and alkali catalystThe reagent piperidine (0.1 mL). And (3) carrying out reflux reaction on the mixed reactants for 24 hours, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-8, wherein the yield is 75.5%, and the m.p.238-240 ℃.1H NMR(400MHz,CD3Cl)δ：1.43～1.65(6H,m,2×CH3) 3.15 to 3.72(7H, m, piperazine-H), 4.72(2H, q, N-CH)2) 7.53-8.14 (6H, m, Ph-H, 5-H and 2 '-H), 8.65(1H, d, 3' -H),9.04(1H, s, 2-H); MS (m/z): 516 and 518[ M + H]+(79Br and81br), calculating (C)25H24F2BrN3O2)：516.39。
Example 9
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (4-nitrocinnamoyl) -quinolin-4 (1H) -one (I-9) having the chemical formula:
namely, Ar in the formula I is p-nitrophenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.54g (3.6mmol) of 4-nitrobenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 24 hours, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal, namely a formula I-9, wherein the yield is 76.8%, and the m.p.247-249 ℃.1H NMR(400MHz,CD3Cl)δ：1.47～1.73(6H,m,2×CH3) 3.15 to 3.78(7H, m, piperazine-H), 4.76(2H, q, N-CH)2) 7.48(1H, d, 2 '-H), 8.54-8.87 (5H, 3' -H and Ph-H),9.17(1H, s, 2-H); MS (m/z): 483 calculate (C)25H24F2N4O4)：482.49。
Example 10
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- (4-hydroxy-cinnamoyl) -quinolin-4 (1H) -one (I-10) having the chemical formula:
namely, Ar in the formula I is 4-hydroxy-phenyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.49g (4.0mmol) of 4-hydroxy-benzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal, namely a formula I-10, wherein the yield is 68.5%, and the m.p.236-238 ℃.1H NMR(400MHz,CD3Cl)δ：1.41～1.66(6H,m,2×CH3) 2.86 to 3.57(7H, m, piperazine-H), 4.67(2H, q, N-CH)2) 7.44-7.86 (6H, m, Ph-H, 5-H and 2 '-H), 8.57(1H, d, 3' -H),8.93(1H, s,2-H), 10.62(1H, s, OH); MS (m/z): 454, calculating (C)25H25F2N3O3)：453.49。
Example 11
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- [3- (pyridin-3-yl) acryloyl ] -quinolin-4 (1H) -one (I-11) having the chemical structure:
namely, Ar in the formula I is 3-pyridyl.
The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.37g (3.6mmol) of 3-pyridylaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 15h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal shown as a formula I-11, wherein the yield is 87.6%, and the m.p.243-245 ℃.1H NMR(400MHz,CD3Cl)δ：1.46～1.73(6H,m,2×CH3) 3.16 to 3.77(7H, m, piperazine-H), 4.76(2H, q, N-CH)2)，7.56(1H，d2 '-H), 8.45-9.16 (6H, 5-H, 3' -H and pyridine-H), 9.17(1H, s, 2-H); MS (m/z): 439 (C) is calculated24H24F2N4O2)：438.48。
Example 12
1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -3- [3- (furan-2-yl) acryloyl ] quinolin-4 (1H) -one (I-12) having the chemical structure:
namely, Ar in the formula I is 2-furyl.
The preparation method of the compound comprises the following steps: the preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1-ethyl-6, 8-difluoro-7- (3-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.38g (4.0mmol) of 2-furfural and piperidine (0.1mL) as a base catalyst were added. And (3) refluxing and reacting the mixed reactants for 18h, standing at room temperature, filtering and collecting generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal, namely a formula I-12, wherein the yield is 66.5%, and the m.p.235-237 ℃.1H NMR(400MHz,CD3Cl)δ：1.42～1.65(6H,m,2×CH3) 3.06-3.57 (7H, m, piperazine-H), 4.68(2H, q, N-CH)2) 7.22-8.16 (5H, m, 2 '-H, 5-H and furan-H), 8.62(1H, d, 3' -H),9.08(1H, s, 2-H); MS (m/z): 428[ M + H]+Calculating (C)23H23F2N3O3)：427.45。
Test examples
In one embodiment, examples 1 to 12 provide an in vitro antitumor activity assay of an acrylketone derivative of lomefloxacin
1. Test sample
Taking 15 lomefloxacin allyl derivatives provided in examples 1-12 and the classical antitumor TOPO inhibitor 10-Hydroxycamptothecin (HC), the chalcone tyrosinase inhibitor Sunitinib (SN), the broad-spectrum anticancer drug Doxorubicin (DOX) and the parent compound Lomefloxacin (LMF) as test samples, wherein HC, SN and LMF are control experimental groups, and the samples in examples 1-12 are test experimental groups;
thiazole blue (MTT), HC, SN and LMF are all products of Sigma company; the RPMI-1640 culture solution is a product of GIBCO company; other used reagents are all domestic analytical pure reagents.
The experimental cancer cell strains are respectively a human non-small cell lung cancer cell strain A549, a human kidney cancer cell strain 769-P, a human hepatoma cell strain Hep-3B, a human gastric cancer cell strain HGC27, a human pancreatic cancer cell strain Panc-1 and a human leukemia cell strain HL60, which are purchased from Shanghai cell banks of Chinese academy of sciences. The human renal clear cell carcinoma cell sunitinib-resistant strain 7SuR was purchased from shanghai zel biotechnology limited, and the normal cell was obtained from african green monkey kidney cell line VERO and purchased from shanghai tong biology limited.
2. Measurement method
The determination method comprises the following specific steps:
1) firstly, the 15 samples were dissolved in dimethyl sulfoxide (DMSO) to prepare 1.0X 10- 4mol·L-1Stock solution of concentration, then diluting the stock solution with 10% calf serum RPMI-1640 culture solution to have 5 concentration gradients (0.1, 1.0, 5.0, 10.0, 50.0 μmol. L)-1) The working fluid of (1);
2) taking non-small cell lung cancer cell strain A549, human kidney cancer cell strain 769-P, human liver cancer cell strain Hep-3B, human gastric cancer cell strain HGC27, human pancreatic cancer cell strain Panc-1, human leukemia cell strain HL60, human renal clear cell cancer cell sunitinib drug-resistant strain 7SuR and African green monkey kidney cell strain VERO in logarithmic growth phase, inoculating 6000 cells in each hole to a 96-hole plate, then respectively adding working solution with 5 concentration gradients of the 15 samples, and adding 5 g.L.in each hole after 48 hours–1mu.L of MTT (thiazole blue) solution was added, and after further culturing for 4 hours, 100. mu.L of a 10% by mass Sodium Dodecyl Sulfate (SDS) solution was added. Culturing for 24 hours, and then measuring an absorbance (OD) value at a wavelength of 570nm by using a microplate reader;
3) the inhibition rate of the test samples with different concentrations on the cancer cells is calculated according to the following formula,
cancer cell inhibition rate ═ [ (1-experimental OD value)/control OD value ] × 100%;
then, linear regression is carried out on the cancer cell inhibition rate corresponding to each concentration by the pair value of each concentration of the test sample to obtain a dose-effect equation, and the half Inhibition Concentration (IC) of the test sample to the experimental cancer cell is calculated from the obtained dose-effect equation50) (ii) a Each data was measured in triplicate and averaged, the results are shown in Table 1.
TABLE 1 antitumor Activity (IC) of the test samples50)
As can be seen from table 1, the inhibitory activity of the compounds provided in examples 1 to 12 on 7 cancer cells of the experiment is significantly stronger than that of the parent compound lomefloxacin, especially the growth inhibitory activity of some compounds on human non-small cell lung cancer cell line a549 is stronger than that of the control Hydroxycamptothecin (HC), the tyrosine kinase inhibitors Sunitinib (SN) and Doxorubicin (DOX), and the IC of the compounds is IC50The value is reached or close to nanomolar concentration, and the method has the value of new drug development. More significantly, the compounds provided in examples 1 to 12 also show extremely strong sensitivity to sunitinib-resistant strain 7SuR, show strong drug-resistant activity, and simultaneously show low toxicity to normal cells VERO, and have the property of becoming drug-resistant. Therefore, according to the general approach of drug development, the conventional antitumor in vitro screening is carried out, and then the targeted research is carried out, so that the compound has strong antitumor activity, drug resistance activity and lower cytotoxicity, and can be used for preparing antitumor drugs by salifying with acid acceptable for human bodies or mixing with medicinal carriers.
Claims (5)
1. The allyl ketone derivative of lomefloxacin is characterized by being a typical compound with the following structure:
2. the preparation method of the allyl ketone derivative of lomefloxacin according to claim 1, which comprises the following specific steps:
1) taking lomefloxacin shown in a formula II as a raw material, reacting with Carbonyldiimidazole (CDI) to prepare a lomefloxacin imidazole amide compound shown in a formula III, and then carrying out condensation reaction with monoethyl malonate potassium salt to prepare a C-3 formylethyl acetate compound of the lomefloxacin shown in a formula IV; finally, the lomefloxacin C-3 ethanone shown in the formula V is prepared by hydrolysis decarboxylation reaction of the formula IV:
2) the lomefloxacin allyl derivative shown in claim 1 can be prepared by carrying out Claisen-Schmidt condensation reaction on lomefloxacin C-3 ethanone shown in formula V and aromatic aldehyde under the catalysis of alkali to form an allyl ketone structure and carrying out post-treatment.
3. The method for producing an acrylketone derivative of lomefloxacin according to claim 2, wherein the molar ratio of lomefloxacin represented by the formula II to CDI is 1:1.0 to 2.0, the molar ratio of lomefloxacin imidazole amide represented by the formula III to monoethyl malonate potassium salt is 1:1.0 to 1.5, and the molar ratio of lomefloxacin-3 ethanone represented by the formula V to aromatic aldehyde is 1:1.0 to 2.0.
4. The use of the allyl ketone derivative of lomefloxacin as claimed in claim 1 in the preparation of an anti-tumor medicament.
5. The use of the allyl ketone derivative of lomefloxacin as claimed in claim 4, wherein the antitumor drug is a drug for treating human non-small cell lung cancer, kidney cancer, liver cancer, stomach cancer, pancreatic cancer or leukemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911139921.5A CN112824397B (en) | 2019-11-20 | 2019-11-20 | Lomefloxacin propenone derivative and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911139921.5A CN112824397B (en) | 2019-11-20 | 2019-11-20 | Lomefloxacin propenone derivative and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112824397A true CN112824397A (en) | 2021-05-21 |
| CN112824397B CN112824397B (en) | 2023-08-11 |
Family
ID=75906799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911139921.5A Active CN112824397B (en) | 2019-11-20 | 2019-11-20 | Lomefloxacin propenone derivative and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112824397B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113956251A (en) * | 2021-10-26 | 2022-01-21 | 河南大学 | Isoleucinine analogs, preparation method and application of isoleucinine analogs from lomefloxacin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103694242A (en) * | 2013-12-10 | 2014-04-02 | 中国科学院昆明植物研究所 | Pyrazolopyrimidine compound and pharmaceutical composition thereof as well as pharmaceutical application of pyrazolopyrimidine compound |
| CN106317014A (en) * | 2015-06-19 | 2017-01-11 | 河南大学 | Lomefloxacin alpha, beta-unsaturated ketone derivative and preparation method and application thereof |
-
2019
- 2019-11-20 CN CN201911139921.5A patent/CN112824397B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103694242A (en) * | 2013-12-10 | 2014-04-02 | 中国科学院昆明植物研究所 | Pyrazolopyrimidine compound and pharmaceutical composition thereof as well as pharmaceutical application of pyrazolopyrimidine compound |
| CN106317014A (en) * | 2015-06-19 | 2017-01-11 | 河南大学 | Lomefloxacin alpha, beta-unsaturated ketone derivative and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| TAKUO KOSUGE ET AL.: "Synthesis and Some Reactions of 6-Bromooxindole" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113956251A (en) * | 2021-10-26 | 2022-01-21 | 河南大学 | Isoleucinine analogs, preparation method and application of isoleucinine analogs from lomefloxacin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112824397B (en) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106256823B (en) | A kind of α of gatifloxacin, alpha, beta-unsaturated ketone derivative and its preparation method and application | |
| CN108117516B (en) | Preparation method and application of polysubstituted pyridine derivative | |
| CN111303026A (en) | Propenone derivative of enrofloxacin and preparation method and application thereof | |
| CN112824391B (en) | Gatifloxacin propenone derivative and preparation method and application thereof | |
| CN112824415A (en) | Ofloxacin acrylketone derivative and preparation method and application thereof | |
| CN111303189A (en) | Propenone derivative of rufloxacin, and preparation method and application thereof | |
| CN111303027A (en) | Fluroxacin acrylketone derivative and preparation method and application thereof | |
| CN111303190A (en) | Propenone derivative for removing N-methylrufloxacin and preparation method and application thereof | |
| CN111646974A (en) | N-methyl gatifloxacin propenone derivative and preparation method and application thereof | |
| CN112824397B (en) | Lomefloxacin propenone derivative and preparation method and application thereof | |
| CN111646975B (en) | N-methyl lomefloxacin allyl ketone derivative and preparation method and application thereof | |
| CN112824396B (en) | Acrylic ketone derivative of N-acetyl lomefloxacin and preparation method and application thereof | |
| CN111646937B (en) | Propenone derivative of N-acetyl ciprofloxacin and preparation method and application thereof | |
| CN106279019A (en) | A kind of α of enrofloxacin, alpha, beta-unsaturated ketone derivant and its preparation method and application | |
| CN111647004B (en) | Propenone derivative for removing N-methylofloxacin and preparation method and application thereof | |
| CN106316947B (en) | A kind of α of Norfloxacin, alpha, beta-unsaturated ketone derivative and its preparation method and application | |
| CN106316948B (en) | A kind of α of N- methyl Ciprofloxacin, alpha, beta-unsaturated ketone derivative and its preparation method and application | |
| CN112824414A (en) | Propenone derivative of N-acetylofloxacin and preparation method and application thereof | |
| CN111320578A (en) | Propenone derivative for removing N-methylfleroxacin and preparation method and application thereof | |
| CN112824416A (en) | Propenone derivative for removing N-methyllevofloxacin, and preparation method and application thereof | |
| CN111393453A (en) | Acrylketone derivative of levofloxacin, and preparation method and application thereof | |
| CN112824390B (en) | Acrylic ketone derivative of ciprofloxacin and preparation method and application thereof | |
| CN112824401B (en) | Acrylic ketone derivative of N-acetyl gatifloxacin and preparation method and application thereof | |
| CN112824405B (en) | Acrylic ketone derivative of N-methyl enoxacin and preparation method and application thereof | |
| CN112824388B (en) | Acrylic ketone derivative of norfloxacin and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |